Skip to main content

ACTIVIDAD HIPOXIMIMETICA DE NUEVOS DERIVADOS DEL CANNABIDIOL. IMPLICACIONES TERAPEUTICAS

SAF2014-53763-P

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D (Excelencia / Generación de Conocimiento)
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSIDAD DE CORDOBA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy

  • Navarrete, Carmen
  • Carrillo-Salinas, F. J.
  • Palomares, Belén
  • Mecha, Miriam
  • Jiménez-Jiménez, Carla
  • Mestre, Leyre
  • Feliú, Ana
  • Bellido, María Luz
  • Fiebich, Bernd L.
  • Appendino, Giovanni
  • Calzado, Marco A.
[Background] Multiple sclerosis (MS) is characterized by a combination of inflammatory and neurodegenerative processes variously dominant in different stages of the disease. Thus, immunosuppression is the goal standard for the inflammatory stage, and novel remyelination therapies are pursued to restore lost function. Cannabinoids such as 9Δ-THC and CBD are multi-target compounds already introduced in the clinical practice for multiple sclerosis (MS). Semisynthetic cannabinoids are designed to improve bioactivities and druggability of their natural precursors. VCE-004.8, an aminoquinone derivative of cannabidiol (CBD), is a dual PPARγ and CB2 agonist with potent anti-inflammatory activity. Activation of the hypoxia-inducible factor (HIF) can have a beneficial role in MS by modulating the immune response and favoring neuroprotection and axonal regeneration., [Methods] We investigated the effects of VCE-004.8 on the HIF pathway in different cell types. The effect of VCE-004.8 on macrophage polarization and arginase 1 expression was analyzed in RAW264.7 and BV2 cells. COX-2 expression and PGE2 synthesis induced by lipopolysaccharide (LPS) was studied in primary microglia cultures. The efficacy of VCE-004.8 in vivo was evaluated in two murine models of MS such as experimental autoimmune encephalomyelitis (EAE) and Theiler’s virus-induced encephalopathy (TMEV)., [Results] Herein, we provide evidence that VCE-004.8 stabilizes HIF-1α and HIF-2α and activates the HIF pathway in human microvascular endothelial cells, oligodendrocytes, and microglia cells. The stabilization of HIF-1α is produced by the inhibition of the prolyl-4-hydrolase activity of PHD1 and PDH2. VCE-004.8 upregulates the expression of HIF-dependent genes such as erythropoietin and VEGFA, induces angiogenesis, and enhances migration of oligodendrocytes. Moreover, VCE-004.8 blunts IL-17-induced M1 polarization, inhibits LPS-induced COX-2 expression and PGE2 synthesis, and induces expression of arginase 1 in macrophages and microglia. In vivo experiments showed efficacy of VCE-004.8 in EAE and TMEV. Histopathological analysis revealed that VCE-004.8 treatments prevented demyelination, axonal damage, and immune cells infiltration. In addition, VCE-004.8 downregulated the expression of several genes closely associated with MS physiopathology, including those underlying the production of chemokines, cytokines, and adhesion molecules., [Conclusions] This study provides new significant insights about the potential role of VCE-004.8 for MS treatment by ameliorating neuroinflammation and demyelination., This work was supported by grants SAF2014-53763-P (EM), SAF2017-87701-R (EM), and SAF2016-76449-R (GC) from the Ministry of the Economy and Competition (MINECO) co-financed with the European Union FEDER funds. GC was also supported by the Red Española de Esclerosis Múltiple (REEM: RD16/0015/0021) sponsored by the Fondo de Investigación Sanitaria (FIS); MAC was supported by the Instituto de Salud Carlos III (PIE14/00005) co-funded by the European Regional Development Fund/European Social Fund “Investing in your future”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Effect of oral VCE-004.8, a cannabidiol quinol derivative, on experimental autoimmune encephalomyelitis

  • Navarrete, Carmen
  • García, Adela
  • Palomares, Belén
  • Mestre, Leyre
  • Mecha, Miriam
  • Feliú, Ana
  • Garrido, Martín
  • Calzado, Marco A.
  • Bellido, María Luz
  • Guaza, Carmen
  • Muñoz, Eduardo
Trabajo presentado en el 28th Annual Symposium of the International Cannabinoid Research Society, celebrado en Leiden del 30 de junio al 5 de julio de 2018., Multiple Sclerosis (MS) is characterized by a combination of inflammatory and neurodegenerative processes that are dominantin different stages of the disease. Thus, immunosuppression is the goldstandard for the inflammatory stage and novel remyelination therapies are being pursued to restore lost function. While angiogenesis andblood-brain barrier(BBB)disruption are potentially negative in inflammatory phases, angiogenesis mediated by the stabilization of HIF-1αcould be beneficial for neuroprotection and axonal regeneration in remitting phases and progressive forms of the disease. Therefore, the development of complementary treatments aimed at axonal repair and remyelination and/or slowing the progression of the disease through neuroprotectionand axonal regeneration remain the most important objective in the clinical management of chronic progressive MS., Acknowledgements: Partially funded by MINECO grants SAF2014-53763-P and SAF2017-87701-R to EM., Peer reviewed